Frontiers in microbiology · 2026
Emergence of ST1076 as a dominant high-risk clone carrying bla KPC-2 in carbapenem-resistant Pseudomonas aeruginosa from Deqing, Zhejiang, China: a 5-year genomic epidemiology study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shou Xiaolan, Li Xiangchen, Yang Hongyin, Zhang Xiaofan
Аннотация
BACKGROUND: Carbapenem-resistant Pseudomonas aeruginosa (CRPA) is a major healthcare-associated pathogen with high multidrug resistance and mortality. Regional clonal spread of high-risk lineages carrying carbapenemase genes poses significant challenges for infection control.
METHODS: We analyzed 100 non-duplicate CRPA clinical isolates collected from June 2020 to December 2024 in Deqing, Zhejiang Province, China. Antimicrobial susceptibility was determined by automated systems, and molecular characterization was performed via whole-genome sequencing, multilocus sequence typing (MLST), core-genome single nucleotide polymorphism (SNP) phylogeny, resistance and virulence gene profiling, and phylogeographic analysis.
RESULTS: The observed resistance rates were 95% for imipenem and 91% for meropenem. Carbapenemase-producing isolates comprised 44% (44/100), with bla KPC-2 predominating (95.5%, 42/44). MLST identified 44 sequence types, including novel ST5216. ST1076 was the dominant clone (23%, 23/100), followed by ST463 (17%). Among ST1076 isolates, 87.0% carried bla KPC-2. Core-genome SNP analysis revealed tight clustering of 22/23 ST1076 isolates (4-105 SNPs), suggesting possible prolonged nosocomial transmission centered in the Intensive Care Unit (ICU) since mid-2020. Phylogeographic analysis showed strong clustering with ST1076 strains from Ningbo and Hangzhou, supporting intra-provincial dissemination within Zhejiang. Virulence profiling demonstrated high prevalence of T3SS effectors (exoT 100%, exoY 97%) and frequent oprD inactivation.
CONCLUSION: This study reveals the emergence and sustained ICU-associated transmission of bla KPC-2-harboring ST1076 CRPA as a regionally dominant clone in Zhejiang, China, while preserving high susceptibility to ceftazidime/avibactam (CZA). Enhanced local surveillance and strict infection control measures are urgently needed to prevent further spread of this high-risk lineage.
METHODS: We analyzed 100 non-duplicate CRPA clinical isolates collected from June 2020 to December 2024 in Deqing, Zhejiang Province, China. Antimicrobial susceptibility was determined by automated systems, and molecular characterization was performed via whole-genome sequencing, multilocus sequence typing (MLST), core-genome single nucleotide polymorphism (SNP) phylogeny, resistance and virulence gene profiling, and phylogeographic analysis.
RESULTS: The observed resistance rates were 95% for imipenem and 91% for meropenem. Carbapenemase-producing isolates comprised 44% (44/100), with bla KPC-2 predominating (95.5%, 42/44). MLST identified 44 sequence types, including novel ST5216. ST1076 was the dominant clone (23%, 23/100), followed by ST463 (17%). Among ST1076 isolates, 87.0% carried bla KPC-2. Core-genome SNP analysis revealed tight clustering of 22/23 ST1076 isolates (4-105 SNPs), suggesting possible prolonged nosocomial transmission centered in the Intensive Care Unit (ICU) since mid-2020. Phylogeographic analysis showed strong clustering with ST1076 strains from Ningbo and Hangzhou, supporting intra-provincial dissemination within Zhejiang. Virulence profiling demonstrated high prevalence of T3SS effectors (exoT 100%, exoY 97%) and frequent oprD inactivation.
CONCLUSION: This study reveals the emergence and sustained ICU-associated transmission of bla KPC-2-harboring ST1076 CRPA as a regionally dominant clone in Zhejiang, China, while preserving high susceptibility to ceftazidime/avibactam (CZA). Enhanced local surveillance and strict infection control measures are urgently needed to prevent further spread of this high-risk lineage.